Claims for Patent: 11,229,640

Summary for Patent: 11,229,640

Title:	Combination of dextromethorphan and bupropion for treating depression
Abstract:	Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Inventor(s):	Herriot Tabuteau
Assignee:	Antecip Bioventures II LLC
Application Number:	US17/066,310
Patent Claims:	1. A method of treating depression, comprising orally administering a dosage form once a day or twice a day to a human being in need thereof, wherein the dosage form comprises about 90 mg to about 125 mg of bupropion and about 40 mg to about 70 mg of dextromethorphan, wherein bupropion and dextromethorphan are the only therapeutically active compounds in the dosage form, and wherein the dosage form is orally administered to the human being for at least 8 consecutive days. 2. The method of claim 1, wherein the human being experiences an improvement in a depressive symptom as compared to baseline. 3. The method of claim 1, wherein orally administering the dosage form is more effective in treating treatment resistant depression than a placebo. 4. The method of claim 1, wherein orally administering the dosage form is more effective in treating treatment resistant depression than orally administering the same amount of the dextromethorphan alone. 5. The method of claim 1, wherein the dosage form is orally administered to the human being once a day. 6. The method of claim 1, wherein the dosage form is orally administered to the human being twice a day. 7. The method of claim 1, wherein the dosage form is orally administered to the human being for at least 14 consecutive days. 8. The method of claim 1, wherein the dosage form is orally administered to the human being for at least 30 consecutive days. 9. The method of claim 1, wherein the weight ratio of the dextromethorphan to the bupropion in the dosage form is about 0.3 to about 0.5. 10. The method of claim 1, wherein the dosage form is solid. 11. The method of claim 1, wherein the dosage form is orally administered to the human being once a day for 1 day and is administered to the human being twice a day thereafter. 12. The method of claim 1, wherein the dosage form is orally administered to the human being once a day for 2 days and is administered to the human being twice a day thereafter. 13. The method of claim 1, wherein the dosage form is orally administered to the human being once a day for 3 days and is administered to the human being twice a day thereafter. 14. The method of claim 1, wherein the dosage form comprises about 105 mg of bupropion hydrochloride, or a molar equivalent amount of bupropion in the free base or another salt form; and about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of dextromethorphan in the free base or another salt form. 15. The method of claim 14, wherein orally administering the dosage form is more effective than a placebo in reducing anxiety. 16. The method of claim 14, wherein orally administering the dosage form is more effective than a placebo in improving concentration, reducing mental slowing, or a combination thereof. 17. The method of claim 14, wherein orally administering the dosage form is more effective than a placebo in improving mood, reducing feelings of intense sadness, reducing despair, reducing pessimistic worry, or a combination thereof. 18. The method of claim 14, wherein orally administering the dosage form is more effective than a placebo in reducing agitation, irritability, restlessness, or a combination thereof. 19. The method of claim 14, wherein orally administering the dosage form is more effective than a placebo in reducing guilt, feelings of worthlessness, self-deprecation, or a combination thereof. 20. The method of claim 14, wherein orally administering the dosage form is more effective than a placebo in reducing anger, reckless behavior, suicidal thoughts or attempts, or a combination thereof. 21. The method of claim 14, wherein orally administering the dosage form is more effective than a placebo in reducing insomnia. 22. The method of claim 14, wherein orally administering the dosage form is more effective than a placebo in reducing anorexia, appetite loss, weight loss, or a combination thereof. 23. The method of claim 14, wherein orally administering the dosage form is more effective than a placebo in reducing weight gain. 24. The method of claim 14, wherein orally administering the dosage form is more effective than a placebo in reducing decreased energy, fatigue, decreased libido, or a combination thereof. 25. The method of claim 14, wherein orally administering the dosage form is more effective than a placebo in reducing aches, pains, headaches, cramps, or a combination thereof. 26. The method of claim 14, wherein orally administering the dosage form is more effective than a placebo in reducing digestive issues. 27. The method of claim 14, wherein orally administering the dosage form is more effective than a placebo in reducing abnormal hormonal circadian rhythms.